Fig. 2

Flow cytometric analyses for determining the circulating levels of inflammatory cells, immune cells and apoptotic mononuclear cells, and mortality rate by day 5 after SS-AKIR procedure. A Analytical result of number of early apoptosis (AN-V+/PI−) of circulatory mononuclear cells. B Analytical result of number of late apoptosis (AN-V+/PI+) of circulatory mononuclear cells. C Analytical result of circulatory number of CD11b/c + cells. D Analytical result of circulatory number of Ly6G + cells. E Analytical result of circulatory number of CD3/CD4+ cells. F Analytical result of splenic number of CD3/CD4+ cells. G Analytical result of circulatory number of CD3/CD8a+ cells. H Analytical result of splenic number of CD3/CD8a+ cells. I Analytical result of circulatory number of Treg+ (i.e., CD4+/CD25+ /Foxp3 +) cells. J Analytical result of splenic number of Treg + cells. K Illustrating the K-M survival curve. L The mortality rate. n = 6 for each group; on the other hand, for mortality analysis: n = 10 in G1; n = 24 in G2; n = 12 in G3; n = 12 in G4; n = 12 in G5; n = 10 in G6. * indicates p value  < 0.05; ** indicates p value  < 0.01; *** indicates p value  < 0.001; **** indicates p value  < 0.0001. G2 = sepsis syndrome (SS) + acute kidney ischemia–reperfusion (AKIR); G3 (SS + AKIR + ciprofloxacin administered at 3 h after SS-AKIR induction); G4 [SS + AKIR + iPS-MSCs by intravenous injection at 3 h, after SS-AKIR (i.e., defined as early treatment)]; G5 [SS + AKIR + iPS-MSCs by intravenous injection at 18 h after SS-AKIR (i.e., defined as late treatment) after SS-AKIR induction]; G6 [SS + AKIR + ciprofloxacin and iPS-MSCs at 3 h after SS-AKIR induction]. iPS-MSCs = induced pluripotent stem cells-derived mesenchymal stem cells